Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Lumigan Unsubstantiated Superiority Claims Cited In FDA Warning Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

The company must send corrective messages regarding the violative sales aid for Lumigan that contains misleading claims regarding the superiority of the ocular therapy, FDA says.

You may also be interested in...



Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says

Inspire Pharmaceuticals gets a letter from FDA's Division of Drug Marketing, Advertising and Communications for a four-page professional journal ad for its bacterial conjunctivitis treatment AzaSite.

Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says

Inspire Pharmaceuticals gets a letter from FDA's Division of Drug Marketing, Advertising and Communications for a four-page professional journal ad for its bacterial conjunctivitis treatment AzaSite.

FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit

DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.

Related Content

Topics

UsernamePublicRestriction

Register

PS062998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel